PhoenixBio Co (TSE:6190) Short-Term Debt: 円190 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6190 PhoenixBio Co Ltd TSE:6190
51 GF Score
Price 円346.00
GF Value 円363.35
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is PhoenixBio Co Short-Term Debt?

PhoenixBio Co TSE:6190 -0.57% 51 Short-Term Debt is 円190 Mil as of Mar. 2026. GuruFocus rates TSE:6190 with a GF Score™ of 51/100 and a GF Value™ of 円363.35 (Fairly Valued). The stock has 3 warning signs investors should review.

PhoenixBio Co's Short-Term Debt for the quarter that ended in Mar. 2026 was 円190 Mil.

PhoenixBio Co's quarterly Short-Term Debt stayed the same from Sep. 2025 (円180 Mil) to Dec. 2025 (円180 Mil) but then increased from Dec. 2025 (円180 Mil) to Mar. 2026 (円190 Mil).

PhoenixBio Co's annual Short-Term Debt stayed the same from Mar. 2024 (円180 Mil) to Mar. 2025 (円180 Mil) but then increased from Mar. 2025 (円180 Mil) to Mar. 2026 (円190 Mil).

PhoenixBio Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

PhoenixBio Co Short-Term Debt Related Terms

PhoenixBio Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for PhoenixBio Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhoenixBio Co Short-Term Debt Chart

PhoenixBio Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 875.00 179.99 179.99 189.99

PhoenixBio Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179.99 179.99 179.99 179.99 189.99
TSE:6190
51GF Score
PhoenixBio Co Ltd TSE:6190
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of 円190 Mil mean?
PhoenixBio Co (TSE:6190) has a Short-Term Debt of 円190 Mil as of Mar. 2026.
Is PhoenixBio Co's Short-Term Debt too high?
PhoenixBio Co's current Short-Term Debt is 円190 Mil. Overall, PhoenixBio Co has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Short-Term Debt compare to VRTX and REGN?
PhoenixBio Co's Short-Term Debt of 円190 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. PhoenixBio Co's current Short-Term Debt is 円190 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円363.35, compared to a current price of 円346.00 — trading 4.8% below its estimated fair value. The current Short-Term Debt is 円190 Mil. PhoenixBio Co's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Short-Term Debt is 円190 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhoenixBio Co (TSE:6190) Overvalued in 2026?

Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued. The current stock price of 円346.00 is trading 4.8% below its estimated GF Value™ of 円363.35. GuruFocus considers PhoenixBio Co to be Fairly Valued.

Key valuation signals for TSE:6190:

  • Short-Term Debt: 円190 Mil
  • GF Value™: 円363.35 vs. price of 円346.00 (4.8% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PhoenixBio Co Business Description

Address 3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
51GF Score

Get the complete analysis for TSE:6190

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円346.00
Price
円363.35
GF Value